BiotechTube
StemCyte

StemCyte

Covina, United States· Est.
stemcyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

StemCyte is an established leader in the cord blood banking and regenerative medicine sector, uniquely positioned with a dual private/public banking model. The company has a strong clinical footprint, having provided units for 1 out of every 26 cord blood transplants worldwide and actively participating in numerous clinical trials. A significant recent milestone is the U.S. FDA approval of its Biologics License Application (BLA) for REGENECYTE™, marking its transition into a commercial-stage cell therapy developer. StemCyte's integrated approach—from biobanking to advanced therapy development—creates a vertically differentiated platform in the cellular therapeutics space.

HematologyNeurologyImmunologyPost-COVID Syndrome

Technology Platform

Proprietary cord blood and tissue processing (MaxCell method), large-scale GMP biobanking, and FDA-approved manufacturing for cord blood-derived cell therapies.

Funding History

3
Total raised:$80M
Debt$15M
Series B$40M
Series A$25M

Opportunities

The FDA approval of REGENECYTE™ opens the large commercial cell therapy market.
Expanding clinical trials into neurological (stroke, cerebral palsy) and inflammatory (post-COVID) conditions addresses massive unmet needs with blockbuster potential.
The hybrid private/public banking model provides a stable revenue base to fund high-margin therapeutic development.

Risk Factors

Clinical failure in high-profile neurological trials could damage the growth narrative.
The private cord blood banking market is competitive and faces consumer education challenges.
As a private company, scaling commercial operations for an approved therapy requires significant capital or a partnership.

Competitive Landscape

In cord blood banking, StemCyte competes with other private banks (e.g., CBR, ViaCord) and public networks. Its clinical track record and FDA approval are key differentiators. In cell therapy, it faces competition from large biopharma and biotechs developing advanced modalities for similar indications, though its off-the-shelf, non-genetically modified cord blood product offers a potentially simpler safety profile.

More companies in Cell & Gene Therapy →More companies in United States →